Chapter

Systemic treatment: targeted therapies

Tanya Dorff and David Quinn

in Renal Cancer

Published on behalf of Oxford University Press

ISBN: 9780199562312
Published online September 2011 | e-ISBN: 9780199607402 | DOI: http://dx.doi.org/10.1093/med/9780199562312.003.0007

Series: Oxford Oncology Library

Systemic treatment: targeted therapies

Show Summary Details

Preview

• The vascular endothelial growth factor (VEGF) pathway is critical for renal cell carcinoma (RCC) survival and metastasis • Multitargeted tyrosine kinase inhibitors (TKIs) which inhibit the VEGF pathway prolong time to disease progression and overall survival in advanced RCC • The mammalian target of rapamycin (mTOR) is aberrant in a significant number of renal cancers and is a second critical pathway in RCC • mTOR inhibitors prolong time to disease progression and overall survival in select groups of patients with RCC • Toxicities of VEGF tyrosine kinase and mTOR inhibitors used for RCC therapy require close monitoring, management, and at times dosage modifications.

Chapter.  3369 words.  Illustrated.

Subjects: Clinical Oncology

Full text: subscription required

How to subscribe Recommend to my Librarian

Buy this work at Oxford University Press »

Users without a subscription are not able to see the full content. Please, subscribe or login to access all content.